Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy

J Am Acad Dermatol. 2003 Feb;48(2):290-3. doi: 10.1067/mjd.2003.228.

Abstract

We describe a patient with widespread and progressive cutaneous sarcoidosis who was successfully treated with anti-tumor necrosis factor-alpha monoclonal antibody, infliximab, suggesting that inhibition of tumor necrosis factor-alpha may be useful as targeted treatment in cutaneous sarcoidosis.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Dermatologic Agents / therapeutic use*
  • Disease Progression
  • Genotype
  • Humans
  • Infliximab
  • Male
  • Sarcoidosis / drug therapy*
  • Sarcoidosis / genetics
  • Skin Diseases / drug therapy*
  • Tumor Necrosis Factor-alpha

Substances

  • Antibodies, Monoclonal
  • Dermatologic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab